Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 55
- 主要终点
- Percentage of effector cells activation and degranulation (CD69 and CD107a staining )
研究概览
简要总结
Although immunotherapy revolutionized melanoma outcomes over the last 10 years, only 40-50% of patients respond to treatments and 25% develop acquired resistances. Natural Killer (NK) cells naturally recognize and kill tumor cells. However, the immunosuppressive micro-environment generated by the tumor decreases NK cells' killing activity. CD160 is a NK cell receptor identified and characterized in our laboratory. Engagement of the GPI isoform (CD160-GPI) initiates NK cell cytotoxic response. Upon NK cell activation, a transmembrane isoform (CD160-TM) is neo-synthesized which promotes the amplification of activated NK cell cytotoxicity.
The aim of this study is to assess the phenotypic profile of advanced stages melanoma patients' NK cells (mainly CD160-TM expression or its induction) and therefore the therapeutic potential of the use of an anti-CD160-TM agonist antibody to boost the NK-dependent mechanism leading to tumor depletion.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •Pregnant and breastfeeding women
- •Patients with psychiatric disorders
- •Patients already included in another clinical trial
- •Having received chemotherapy or radiotherapy during the last 4 weeks,
- •Patient presenting another solid or blood cancer, chronic viral infection (e.g. HIV, HBV or HCV)
- •Been treated with more than 10mg of steroids until the 4 weeks before inclusion.
- •Refusal to participate to the study
- •Patients under guardianship or curatorship
- •Patients on state medical aid
结局指标
主要结局
Percentage of effector cells activation and degranulation (CD69 and CD107a staining )
时间窗: at inclusion
Difference between cells incubated with the anti CD160-TM antibody and with isotipic control ab ( flow cytometry)
次要结局
- Overall survival(at 5 years post inclusion)
- Phenotypic characteristics of NK cells(at inclusion)
- Progression free survival(at 5 years)
- Objective response rate(at 5 years)
- cytokine profile(at inclusion)
- Détection and quantification of sCD160 in patients' serum(at inclusion)